Hedia and Glooko Team Up to Revolutionize Diabetes Management with Personalized Insulin Dosing

Innovative Collaboration in Diabetes Care

In a progressive move aimed at enhancing diabetes management, Hedia and Glooko have announced their partnership to launch a groundbreaking interoperable solution. This new integration combines connected healthcare, remote patient monitoring, and digital therapeutic technologies, focusing primarily on those with type 1 and type 2 diabetes who require sophisticated bolus insulin dosing support.

Bolus Dosing: An Overview

For individuals managing diabetes, bolus refers to the additional insulin administered to counteract expected spikes in blood glucose levels, typically associated with meals. This dosage varies widely among individuals, presenting a significant challenge for those without insulin pumps. The integration of Glooko's platform enables patients to share their health data with healthcare providers, making it easier to manage these complexities effectively.

Features of the Glooko-Hedia Collaboration

The alliance leverages Glooko's platform that allows patients to seamlessly share critical diabetes-related data, such as blood glucose readings, insulin doses, carbohydrate intake, physical activity levels, blood pressure, and weight. By merging this with the Hedia Diabetes Assistant, the integration provides personalized and hassle-free support for calculating insulin dosages. The goal is to simplify diabetes management and lead to more stable blood glucose levels.

Healthcare providers will also benefit from this collaboration, gaining enhanced insight into their patients' health data through convenient access to comprehensive information. This integrated approach improves the efficiency of managing multiple daily injections (MDI), promoting better patient outcomes and greater efficiency for healthcare providers during both remote and in-person visits.

Statements from the Leaders

Mike Alvarez, CEO of Glooko, expressed enthusiasm for the partnership, stating, "We are excited to provide this personalized algorithm-driven innovation to diabetes patients and their healthcare teams through our collaboration with Hedia. With extensive clinical data supporting Hedia's effectiveness, this solution offers an alternative for those unable to access insulin pumps, ensuring more effective MDI therapy management."

Echoing these sentiments, Lars Christian Lund, CEO of Hedia, highlighted the alignment of the partnership with Hedia's vision to enhance the quality of life for those living with diabetes. He emphasized the importance of regulatory compliance in their technology development, noting the recent receipt of the MDR certification in Europe, which designates Hedia's solution as a class IIb medical device.

About Hedia and Glooko

Hedia stands out as a leader in digital diabetes therapies, dedicated to assisting insulin-dependent individuals in managing their condition more effectively. Their app generates personalized insulin recommendations by incorporating individual habits and various diabetes management factors. Glooko, on the other hand, focuses on improving health outcomes for chronic disease patients through personalized, smart healthcare solutions that connect patients with providers.

This partnership between Hedia and Glooko marks a significant milestone in diabetes care, aiming to foster innovation and improve daily management for millions worldwide. With plans for continued expansion into additional countries in Europe following its initiation in the UK, the future looks promising for diabetes management solutions that prioritize patient well-being and streamlined healthcare processes.